Catalent Announces Two Senior Appointments to its Biologics Business
Somerset, N.J. (PRWEB) September 04, 2014 -- Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the appointment of Brian Riley as General Manager of the company’s biologics manufacturing site in Madison, WI. Dr. Michael Jenkins, who was previously General Manager at the Madison site, has been appointed to the newly created role of VP Business Development, Biologics, Asia Pacific.
Mr. Riley will head the Madison Site Leadership Team. He will be responsible for directing the strategy of the site organization to ensure the attainment of revenue and profit goals, along with Safety, Quality, Delivery and Cost performance, and achievement of current and long-range objectives.
Mr. Riley joins Catalent from BioMerieux, where he was Site Director of Operations and Site Management at their Durham, NC facility. Previously, he had held the position of Director of Quality Operations at BioMerieux and had worked in Quality and Operational roles at both Biogen Idec and Amgen. He holds a B.S. from North Carolina State University and an MBA from Campbell University in North Carolina.
In his new role, Dr. Jenkins will work with Andrew Sandford to drive the Advanced Delivery Technologies, Biologics business growth. Dr. Jenkins will focus in the important emerging markets whilst Mr Sandford, who joined Catalent earlier in the year as VP Business Development, Biologics will focus on the North American and European regions.
Dr. Jenkins joined Catalent Pharma Solutions more than eleven years ago and held senior positions in Commercial Operations and Business Development before becoming General Manager of Catalent's Middleton, WI facility and latterly the new facility in Madison. He was awarded a Ph.D. by the Department of Molecular and Cellular Biology at the University of Arizona, with a minor in Biochemistry, and holds a B.S. in Microbiology from the University of Illinois at Champaign Urbana.
“We would like to take the opportunity to thank Dr. Jenkins who played a key part in the success of our state-of-the-art Madison biologics facility and wish him the best in his new role, which is part of our strategic business development plans in the Asia-Pacific market” commented Catalent’s Barry Littlejohns, President, Advanced Delivery Technologies. “We also welcome Mr. Riley, who joins the company with a great deal of manufacturing management experience and will further grow the biologics business out of Madison as we embark on the next exciting stage of our company’s development.”
Developed in response to customer demand, Catalent’s Madison biomanufacturing facility, constructed through an investment of approximately $20m and completed in June 2013, quadrupled the company’s biologics manufacturing capacity. Designed for flexible cGMP production from 10L up to 1000L, and non-GMP production up to 250L, the site features single-use technologies and unidirectional flow to maximize efficiency and safety.
About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,000 people, including over 1,000 scientists, at 27 facilities across 5 continents. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com
More products. Better treatments. Reliably supplied.™
Chris Halling, Catalent Pharma Solutions, http://www.catalent.com, +44 7580041073, [email protected]
Share this article